Gut Microbiota Signatures Associate with Chemotherapy-Related Adverse Events in Breast Cancer Patients
Signaturen der Darmmikrobiota bei chemotherapiebedingten Nebenwirkungen bei Brustkrebspatient:innen
Cancers · 26.11.2025 · 17 (23) · 3783
DOI: 10.3390/cancers17233783 ↗Auf einen Blick
Bei 81 Brustkrebspatient:innen unter Chemotherapie zeigten sich Zusammenhänge zwischen Darmmikrobiom und mehreren Nebenwirkungen. Besonders starke Assoziationen fanden sich bei schwerer Anämie, Neutropenie, Thrombozytopenie und Hepatotoxizität.
Fragestellung
Welche Zusammenhänge bestehen zwischen Veränderungen der Darmmikrobiota und chemotherapiebedingten Nebenwirkungen bei Brustkrebspatient:innen?
Methode
Prospektive Kohortenstudie mit 81 Brustkrebspatient:innen unter Chemotherapie von Mai 2018 bis Oktober 2022; 16S-rRNA-Sequenzierung, LEfSe, Cohen’s d mit 95 %-KI und FDR-Korrektur.
Ergebnisse
42 Taxa zeigten signifikante Mikrobiom-Toxizitäts-Assoziationen (FDR q < 0,05; d = −1,60 bis +1,67). Schwere Anämie war mit Eubacteriaceae, Anaerofilum und Eubacterium angereichert; Neutropenie mit weniger Eubacterium_hallii_group.
Schlussfolgerung der Autor:innen
Spezifische Signaturen der Darmmikrobiota waren mit unterschiedlichen chemotherapiebedingten Nebenwirkungen assoziiert und könnten als Biomarker für Toxizitätsvorhersage und personalisierte Krebstherapie dienen.
Kernaussagen
- 42 Taxa mit signifikanten Assoziationen
- Schwere Anämie: Eubacteriaceae, Anaerofilum, Eubacterium angereichert
- Neutropenie: Eubacterium_hallii_group vermindert
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 26.11.2025. Verfasst von Jiun-Wei Hsu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, MacKay Memorial Hospital, Taipei 104217, Taiwan. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council (NSTC), Taiwan, Mackay Memorial Hospital, National Science and Technology Council.
Themen: Onkologische Pflege, Patientensicherheit
Abstract (Originalsprache)
Background/Objectives: Chemotherapy-induced adverse events significantly impact cancer treatment outcomes and patient quality of life. Emerging evidence suggests that gut microbiota composition may influence individual susceptibility to chemotherapy toxicity. This study investigated associations between gut microbiome alterations and specific chemotherapy-related adverse events in breast cancer patients undergoing cancer treatment.
Methods
We conducted a prospective cohort study of 81 breast cancer patients receiving chemotherapy between May 2018 and October 2022. Gut microbiome composition was analyzed using 16S rRNA sequencing across multiple taxonomic levels. Alpha diversity (Chao1 estimator) and beta diversity (PERMANOVA) analyses were performed to assess microbial richness and community structure. Linear discriminant analysis effect size (LEfSe) identified differentially abundant taxa, with Cohen’s d effect sizes calculated with 95% confidence intervals and false discovery rate correction applied for multiple comparisons.
Results
Significant microbiome-toxicity associations were identified across 42 taxa (FDR q < 0.05, effect sizes d = −1.60 to +1.67). Severe anemia demonstrated the strongest associations, with large effect size enrichment of Eubacteriaceae (d = 1.38), Anaerofilum (d = 1.42), and Eubacterium (d = 1.38). Severe neutropenia was characterized by depletion of butyrate-producing bacteria, particularly Eubacterium_hallii_group (d = −1.08). Thrombocytopenia showed dramatic depletion of Eubacterium limosum (53-fold reduction, d = −1.60). Hepatotoxicity (ALT elevation) was associated with depletion of Eubacterium_hallii_group (d = −0.99) and Burkholderia-Caballeronia-Paraburkholderia (d = −1.19). Hand-foot syndrome exhibited significantly elevated microbial diversity with depletion of Lachnospiraceae taxa. Most adverse events showed enrichment rather than depletion patterns, with 54.8% of significant associations demonstrating medium to large effect sizes.
Conclusions
Specific gut microbiota signatures associated with distinct chemotherapy-related adverse events, suggesting potential microbiome-based biomarkers for toxicity prediction and personalized cancer treatment strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of General Surgery, MacKay Memorial Hospital, Taipei 104217, Taiwan.
- Department of Medicine, Mackay Medical University, New Taipei 252005, Taiwan.
- Department of Medical Oncology, MacKay Memorial Hospital, Taipei 104217, Taiwan.
- Department of Medical Research, MacKay Memorial Hospital, New Taipei City 251404, Taiwan.
- Department of Colorectal Surgery, MacKay Memorial Hospital, Taipei 104217, Taiwan.
ORCID-Profile: Ying-Wen Su, Horng-Woei Yang, Po-Sheng Yang
Förderung
- National Science and Technology Council (NSTC), Taiwan
- Mackay Memorial Hospital
- National Science and Technology Council
Zitieren
APA
Hsu, J. W., Su, Y. W., Tsai, C. H., Lee, C. C., Yang, H. W., Lee, J. J., Hsu, H. H., Lee, F., & Yang, P. S. (2025). Gut Microbiota Signatures Associate with Chemotherapy-Related Adverse Events in Breast Cancer Patients. Cancers, 17(23), 3783. https://doi.org/10.3390/cancers17233783
Vancouver
Hsu JW, Su YW, Tsai CH, Lee CC, Yang HW, Lee JJ, et al. Gut Microbiota Signatures Associate with Chemotherapy-Related Adverse Events in Breast Cancer Patients. Cancers. 2025;17(23):3783. doi:10.3390/cancers17233783
BibTeX
@article{Hsu2025,
author = {Hsu, Jiun-Wei and Su, Ying-Wen and Tsai, Chung-Hsin and Lee, Chi-Chan and Yang, Horng-Woei and Lee, Jie-Jen and Hsu, Hsi-Hsien and Lee, Fang and Yang, Po-Sheng},
title = {Gut Microbiota Signatures Associate with Chemotherapy-Related Adverse Events in Breast Cancer Patients},
journal = {Cancers},
year = {2025},
volume = {17},
number = {23},
pages = {3783},
doi = {10.3390/cancers17233783}
}
EUVIMED